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Aim: To investigated the long-term efficacy of primary stenting for complex aortoiliac artery disease
Methods: The REAL-AI (REtrospective multicenter AnaLysis of primary stenting for AortoIliac artery disease) registry was performed as a multicenter 
registry enrolling consecutive patients undergoing primary stenting for de novo lesion. Between January 2005 and December 2009, a total of 2096 
patients (2601 lesions, age: 71.3 ± 7.5 years, mean follow interval 31±15 months, claudicant: 82.8%) were enrolled. The primary endpoint was 
primary patency, and the secondary endpoints were primary assisted patency and secondary patency.
Result: The mean lesion length was 53±31 mm. In the TASC II classification, 46.2%, 26.7%, 12.0%, 15.2% patients were in classes A, B, C and 
D, respectively. Successful primary stenting was achieved in 97.6%. Perioperative complications occurred in 6.4%. The overall primary patencies 
were 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted-primary and seconday patencies were 97.0%, 92.7% and 91.9%, and 99.0%, 98.7% 
and 98.5% at 1, 3 and 5 years. There is no significant difference of primary patency among the types of stent and TASCII categories. By multivariate 
analysis of various factors that may have affected primary patency, female, diabetes, renal failure, absence of aspirin, RVD<8.0mm and the outflow 
lesion were independent predictors of primary patency.
Conclusion: Primary stenting for aorto-iliac lesion was feasible for as long as 5 years.
